Press releases

• October 11, 2021 - Other press releaseInvitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET
• September 28, 2021 - Regulatory press releaseEisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
• September 10, 2021 - Other press releaseNew data presented at MDS Congress of ABBV-0805 in Parkinson’s disease

Archive

Calendar

• October 21, 2021Interim report January – September 2021
• February 3, 2022Full Year Report 2021

Read more

Interim Report January - September 2021

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – September 2021 on Thursday, October 21, 2021, at 08:00 a.m. CET.

• Webcast

Read the invitation

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more